
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate is on track for a potential approval for CTx-1301 and CTx-1302 in mid-2026, and a subsequent commercialization in early 2027. With a large market potential for its products in the ADHD and anxiety treatment spaces, and a discounted cash flow-based valuation of $320M translating to a 12-month price objective of $20 per share, Cingulate's current valuation presents a very attractive opportunity for investors. While there are risks associated with securing regulatory approval and potential partnership uncertainties, the potential for significant upside outweighs these risks, making Cingulate a strong buy.
Bears say
Cingulate is facing leadership instability as the CEO has been placed on administrative leave for personal issues, and along with ongoing issues, the company has been unable to efficiently work with the FDA to address manufacturing and controls concerns for its lead asset, CTx-1301. Despite the drug's potential as a once-daily, multi-core tablet formulation, the delayed regulatory filing approval decision and continued instability raises concerns for the company's ability to successfully bring CTx-1301 to market, leading to a negative outlook.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares